Publications by authors named "J E Lazarte"
Article Synopsis
- - KRAS mutations are prevalent in lung adenocarcinoma among Black Americans, leading to the exploration of Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) as potential therapies to disrupt hyperactive G-protein signaling caused by mutated RAS proteins.
- - Among 17 PCAIs tested, NSL-YHJ-2-27 and NSL-YHJ-2-46 demonstrated significant potency in affecting KRAS-mutated lung cancer cells, with EC50 values of 2.7 μM and 3.3 μM, and notable changes in MAPK pathway enzyme phosphorylation.
- - Treatment with these PCAIs led to decreased levels of key G-proteins linked to cell migration
Article Synopsis
- The study explores how different COVID-19 booster vaccinations and recovery from Omicron BA.5 infections affect the body's ability to neutralize various Omicron sublineages.
- Bivalent booster recipients showed significantly better neutralization abilities against specific Omicron variants compared to monovalent booster recipients, while individuals recovered from BA.5 had similar neutralizing antibody levels to bivalent recipients.
- Despite enhanced responses, there were limitations in neutralization against newer subvariants, highlighting the necessity for potentially updated vaccines to tackle these evolving strains.
Background And Aims: Severe hypertriglyceridemia (HTG), defined as plasma triglyceride (TG) concentration > 10 mmol/L, is relatively uncommon, and its implications for atherosclerotic cardiovascular disease (ASCVD) risk remain somewhat unclear. We evaluated the association between severe HTG and carotid intima-media thickness (IMT), a marker for ASCVD.
Methods: We studied three clinical cohorts: 88 patients with severe HTG (mean TG level 20.
Prognoses for TNBC remain poor due to its aggressive nature and the lack of therapies that target its "drivers". RASA1, a RAS-GAP or GTPase-activating protein whose activity inhibits RAS signaling, is downregulated in up to 77% of TNBC cases. As such, RAS proteins become hyperactive and similar in effect to mutant hyperactive RAS proteins with impaired GTPase activities.
View Article and Find Full Text PDFArticle Synopsis
- A significant number of atrial fibrillation (AF) cases remain unexplained by known acquired risk factors, leading researchers to explore genetic testing in a young AF population.
- The study involved whole exome sequencing of 200 patients diagnosed with early-onset AF (under 60 years old), filtering genetic variants and classifying them according to established guidelines.
- Results showed a low diagnostic yield (3.0%) for identifying likely pathogenic variants, indicating the need for more research to uncover additional genetic and environmental factors contributing to AF in patients without clear genetic links.